Rising Shigella Cases and Antibiotic Resistance: A Public Health Alert
The United Kingdom Health Security Agency (UKHSA) is reporting a significant increase in Shigella infections, particularly among gay, bisexual and other men who have sex with men (GBMSM). A concerning trend is the rise of antibiotic-resistant strains, complicating treatment and raising public health concerns. This surge necessitates heightened awareness of transmission routes, preventative measures, and appropriate medical intervention.
This isn’t simply a localized outbreak; it reflects a broader global challenge of increasing antimicrobial resistance (AMR). Shigella, a bacterium causing shigellosis – an infection of the intestines – typically manifests as diarrhea (often bloody), fever, and stomach cramps. While usually self-limiting, severe cases require hospitalization, and the emergence of resistance to commonly used antibiotics like azithromycin is creating a critical treatment gap. The UKHSA’s alert underscores the urgent need for improved surveillance, infection control, and responsible antibiotic stewardship.
In Plain English: The Clinical Takeaway
- What’s happening? More people are getting sick with a stomach bug called Shigella, and some of the bugs are becoming harder to treat with antibiotics.
- Who’s at risk? Currently, the highest risk is among men who have sex with men, but anyone can get Shigella through contaminated food or water, or close contact with an infected person.
- What can you do? Practice fine hygiene – wash your hands frequently, especially after using the bathroom and before preparing food. If you have symptoms, spot a doctor.
Understanding the Epidemiology and Transmission
Shigella is highly contagious. Transmission occurs primarily through the fecal-oral route – meaning the bacteria is spread when someone ingests even microscopic amounts of fecal matter from an infected person. This can happen through contaminated food or water, direct contact with an infected individual, or contact with contaminated surfaces. The recent increase among GBMSM suggests sexual transmission is a significant driver, highlighting the importance of safe sex practices. However, outbreaks have also been linked to food handlers and contaminated produce, demonstrating the diverse pathways of infection.
The UKHSA data, as of early April 2026, indicates a 65% increase in reported Shigella cases compared to the same period last year. Crucially, over 60% of isolates tested demonstrate resistance to azithromycin, a first-line treatment. This resistance is often mediated by plasmid-borne genes, facilitating rapid spread between bacteria. The mechanism of action of azithromycin involves inhibiting bacterial protein synthesis by binding to the 23S rRNA of the 50S ribosomal subunit. Resistance develops when mutations or acquired genes alter the ribosomal target site or activate efflux pumps that remove the antibiotic from the bacterial cell.
The Role of Antibiotic Resistance and Treatment Challenges
The rise of antibiotic-resistant Shigella is a direct consequence of antibiotic overuse, and misuse. When antibiotics are used unnecessarily, they create selective pressure, favoring the survival and proliferation of resistant bacteria. The spread of these resistant strains is further exacerbated by international travel and migration. Currently, treatment options for azithromycin-resistant Shigella are limited, often requiring the use of older, potentially more toxic antibiotics like ciprofloxacin. However, resistance to ciprofloxacin is also emerging, creating a worrying scenario.
The European Medicines Agency (EMA) is actively monitoring the situation and collaborating with national health authorities to develop strategies to combat AMR. In the US, the Centers for Disease Control and Prevention (CDC) has issued similar alerts and is conducting ongoing surveillance. Patient access to appropriate diagnostic testing and treatment is paramount. The NHS in the UK is working to ensure that clinicians have access to updated guidelines and that laboratories have the capacity to rapidly identify resistant strains.
| Antibiotic | Susceptibility Rate (UK Isolates, April 2026) | Common Resistance Mechanism |
|---|---|---|
| Azithromycin | 39% | Plasmid-mediated efflux pumps, 23S rRNA mutations |
| Ciprofloxacin | 85% | Mutations in DNA gyrase and topoisomerase IV |
| Ceftriaxone | 98% | Rare, but increasing reports of extended-spectrum beta-lactamase (ESBL) production |
Funding for research into novel antimicrobial agents and alternative treatment strategies is crucial. A significant portion of current AMR research is funded by the National Institutes of Health (NIH) in the US and the Medical Research Council (MRC) in the UK. However, investment remains insufficient to address the scale of the problem.
“The increasing prevalence of antibiotic resistance in Shigella is a serious threat to public health. We need a coordinated global effort to reduce antibiotic use, improve infection control, and develop new treatments.” – Dr. Helen Smith, Senior Epidemiologist, UKHSA.
Prevention Strategies and Public Health Recommendations
Preventing Shigella infection relies on a multi-pronged approach. Key recommendations include:
- Hand Hygiene: Frequent and thorough handwashing with soap and water, especially after using the toilet and before preparing food.
- Food Safety: Proper food handling and preparation practices, including thorough cooking and avoiding cross-contamination.
- Water Safety: Drinking safe, treated water.
- Safe Sex Practices: For GBMSM, practicing safer sex, including using condoms and being aware of potential risks.
- Isolation: Individuals with Shigella infection should avoid preparing food for others and refrain from sexual activity until symptoms have resolved.
Public health campaigns are essential to raise awareness about Shigella and promote preventative measures. The WHO has developed guidelines for the control of diarrheal diseases, including Shigella, which emphasize the importance of sanitation and hygiene. WHO Fact Sheet on Shigellosis
Contraindications & When to Consult a Doctor
Individuals with weakened immune systems (e.g., those undergoing chemotherapy, HIV/AIDS patients) are at higher risk of severe Shigella infection and should be particularly vigilant about preventative measures. Infants and young children are also more vulnerable.
Consult a doctor immediately if you experience:
- High fever (over 101°F / 38.3°C)
- Bloody diarrhea
- Severe abdominal pain
- Signs of dehydration (e.g., decreased urination, dizziness)
Self-treating with antibiotics is strongly discouraged, as it can contribute to the development of antibiotic resistance. A healthcare professional can accurately diagnose the infection and prescribe appropriate treatment based on susceptibility testing.
The current surge in Shigella cases, coupled with the rise of antibiotic resistance, presents a significant public health challenge. Continued surveillance, research, and a concerted effort to promote preventative measures are essential to mitigate the impact of this infection and protect vulnerable populations. The situation demands a proactive and collaborative response from healthcare professionals, public health agencies, and the public alike.
References
- CDC. (2023). Shigella. https://www.cdc.gov/shigella/index.html
- WHO. (2023). Shigellosis. https://www.who.int/news-room/fact-sheets/detail/shigellosis
- European Medicines Agency. (2024). Antimicrobial resistance. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/antimicrobial-resistance
- Hendrix, M. P., et al. (2022). Antimicrobial resistance in Shigella species: A systematic review. Clinical Microbiology Reviews, 35(3), e00083-21. https://doi.org/10.1128/cmr.00083-21
